This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Acorda Therapeutics, Inc.

Drug Names(s): Transacin, NGX-4010, capsaicin

Description: NGX-4010 is a non-narcotic analgesic formulated in a topical patch containing an 8% concentration of synthetic capsaicin. Capsaicin is released from the patch and absorbed into the skin without significant absorption into the bloodstream. NGX-4010 is administered in a physician’s office in a process that involves pre-treating the painful area with a topical anesthetic followed by the application of the patch.

Capsaicin is a TRPV1 agonist. TRPV1 receptors, found in the peripheral and central nervous systems, are involved in the transmission and modulation of pain. Initially, capsaicin causes a burning pain, but later leads to desensitization of the nerves. There may be various mechanisms involved in desensitization, including downregulation or depletion of neuropeptides, downregulation of TRPV1, up-regulation of analgesic substances, and possibly, degradation of nerve fibers.

Deal Structure: NGX-4010 was originally developed by NeurogesX.

Astellas and NeurogesX
In June 2009, NeurogesX and Astellas Pharma Europe announced that the companies entered into an exclusive Distribution, Marketing and License agreement for the commercialization of Qutenza in the European Economic Area (EEA) including the 27 countries of the European Union, Iceland, Norway, and Liechtenstein as well as Switzerland, certain countries in Eastern Europe, the Middle East and Africa.

Under terms of the agreement, Astellas will commercialize Qutenza in the above-mentioned territories and perform certain development of Qutenza including post-marketing commitments, to support Qutenza in the EU market. NeurogesX will receive EUR 30 million (approximately $42 million) for Qutenza commercialization rights, and EUR 5 million (approximately $7 million) for a license option of NGX-1998, the next-generation liquid formulation which uses the same active ingredient as...See full deal structure in Biomedtracker

Partners: Astellas Pharma, Inc. NeurogesX, Inc.

Qutenza News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug